Fig. 1.
Fig. 1. Analysis of blood lymphocytes. / (A) Phenotypic analysis of lymphocyte subsets in patients with myeloma who underwent T-cell–depleted allogeneic BMT followed by prophylactic DLI. (B) Patients with myeloma and lymphoma who did not receive DLI. Lymphocyte reconstitution was determined by flow cytometric analysis of PBMCs. Values represent median absolute cell numbers for total CD3+ (open squares), CD3+CD4+ (open diamonds), CD3+CD8+ (open circles), CD20+(filled triangles), and CD56+ (checked boxes) cells in each sample. (C) Comparison of the number of CD20+ B cells in 3 patient groups: 9 patients with myeloma who received DLI (DLI group), 7 patients with myeloma and B-cell non-Hodgkin lymphoma who did not receive DLI (no-DLI group), and 87 patients with other hematologic malignancies who did not receive DLI (control group).

Analysis of blood lymphocytes.

(A) Phenotypic analysis of lymphocyte subsets in patients with myeloma who underwent T-cell–depleted allogeneic BMT followed by prophylactic DLI. (B) Patients with myeloma and lymphoma who did not receive DLI. Lymphocyte reconstitution was determined by flow cytometric analysis of PBMCs. Values represent median absolute cell numbers for total CD3+ (open squares), CD3+CD4+ (open diamonds), CD3+CD8+ (open circles), CD20+(filled triangles), and CD56+ (checked boxes) cells in each sample. (C) Comparison of the number of CD20+ B cells in 3 patient groups: 9 patients with myeloma who received DLI (DLI group), 7 patients with myeloma and B-cell non-Hodgkin lymphoma who did not receive DLI (no-DLI group), and 87 patients with other hematologic malignancies who did not receive DLI (control group).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal